Avacopan

企业动态No.1 / 西门子医疗FY2025Q2：营收增长6.8%，受关税影响调整每股收益预期近日，西门子医疗发布了截至2025年3月31日的2025财年（FY2025）第二季度（Q2）季报。公司FY2025Q2的设备订单出货比表现优异，达到1.14；可比营收增长6.8%至59.09亿欧元。按业务划分，西门子医疗的影像业务可比营收增长8.7%至32.81亿欧元；调整后息税前利润率表现优异，达22.4%。体外诊断业务可比营收增长1.0%至11.22亿欧元，调整后息税前利润率6.3%。瓦里安业务可比营收增长12.5%至10.41亿欧元；由于设备收入占比大幅提升，调整后息税前利润率为13.2%。临床治疗业务可比营收增长3.7%至5.53亿欧元；调整后息税前利润率表现优异，达18.5%。整体调整后息税前利润率16.6%，显著高于去年同期。公司预计整个FY2025可比营收将在2024财年基础上增长5%至6%；在地缘政治局势发展，特别是多国贸易壁垒及关税上调的背景下，现将调整后每股基本收益预期调整至2.20至2.50欧元（此前为2.35至2.50欧元）。->点击文末阅读原文，解锁完整双语新闻No.2 / 安进2025Q1财报：总收入81亿美元，产品收入增长11%2025年5月1日，安进（NASDAQ：AMGN）发布了2025年第一季度财务业绩。公司总收入增长9%达81亿美元，产品销售收入56.62亿美元，同比增长11%，由销量同比增长14%推动，但部分被6%的净售价下降所抵消。公司共有14款产品在第一季度实现了至少两位数的销售增长，包括瑞百安（依洛尤单抗）、倍利妥（贝林妥欧单抗）、TEZSPIRE（特泽利尤单抗）、EVENITY（罗莫索珠单抗）、特福尼（阿伐可泮）和昕越（伊奈利珠单抗）等（部分产品销售额见下表）。核心产品2025Q1全球销售额商品名总销售额（亿美元）同比增长瑞百安6.5627%Evenity4.4229%普罗力10.9910%昕越0.9114%特福尼0.9076%Tezspire2.8565%欧泰乐4.3711%倍利妥3.7052%预计2025年全年，公司收入在343亿至357亿美元之间。->点击文末阅读原文，解锁完整双语新闻No.3 / 百济神州2025Q1财报：收入增长49%2025年5月7日，百济神州（Nasdaq：ONC；6160.HK；688235.SH）发布2025年第一季度财务业绩。报告期内，公司总收入达11亿美元，同比增长49%；受益于市场需求的强劲增长，百悦泽（泽布替尼）全球销售额达7.92亿美元，同比增长62%。公司收入全部来自产品收入，产品收入的增长主要得益于百悦泽的销售额增长。2025年第一季度，美国继续成为公司最大市场，产品收入达5.63亿美元，上年同期为3.51亿美元。从安进公司获得授权许可的产品和百泽安的销售也对产品收入增长做出贡献。在美国，百悦泽2025年第一季度销售额为5.63亿美元，同比增长60%，主要得益于需求的增长，其中超过60%的季度环比增长来自于在CLL适应证中的扩大使用，因为百悦泽在美国是CLL和所有其他已获批适应证新患者治疗领域的领导者，且市场份额持续提升；在欧洲，百悦泽2025年第一季度的销售额为1.16亿美元，同比增长73%，主要得益于在所有欧洲主要市场的份额提升，包括德国、意大利、西班牙、法国和英国。百泽安（替雷利珠单抗）2025年第一季度销售额为1.71亿美元，同比增长18%。百济神州2025年全年总收入指引为49亿~53亿美元，其中包括收入强劲增长的预期，受益于百悦泽在美国的领先地位以及在欧洲和全球其他重要市场的持续扩张。->点击文末阅读原文，解锁完整双语新闻No.4 / 诺和诺德2025Q1财报：收入781亿丹麦克朗，终止口服GLP-1制剂Ⅰ期临床2025年5月7日，诺和诺德（NYSE：NVO，OMX：NOVO B）公布了2025年第一季度财务业绩。集团收入780.87亿丹麦克朗（约合118.56亿美元），同比增长18%（按固定汇率计算，下同）。营业利润387.91亿丹麦克朗，同比增长20%。按市场划分，美国市场收入443.16亿丹麦克朗，同比增长17%，占收入总额的53%。其他国际市场中，欧洲和加拿大市场收入147.65亿丹麦克朗，同比增长13%；新兴市场收入87.9亿丹麦克朗，同比增长24%；APAC（包括日本、韩国、大洋洲和东南亚）市场收入45.94亿丹麦克朗，同比增长25%；中国市场（含港澳台）收入56.22亿丹麦克朗，同比增长22%。其中中国市场的增长主要来源于以下因素：减肥产品销售收入7.04亿丹麦克朗，GLP-1类降糖药销售收入同比增长26%；胰岛素销售收入无变化；罕见病疗法销售收入同比增长157%。按产品来看，GLP-1制剂全球销售收入达395.74亿丹麦克朗，同比增长11%，其中Ozempic（司美格鲁肽）销售额327.21亿丹麦克朗（+15%），Victoza（利拉鲁肽）销售额11.58亿丹麦克朗（-46%）。胰岛素销售收入149.97亿丹麦克朗，同比增长3%。减肥药销售收入184.24亿丹麦克朗，同比增长65%，其中Wegovy（司美格鲁肽）销售额173.6亿丹麦克朗（+83%），Saxenda（利拉鲁肽）销售额10.64亿丹麦克朗（-35%）。在中国大陆地区，GLP-1降糖制剂市占率高达80.9%，远高于其他市场，报告期内销售额18.01亿丹麦克朗，同比增长26%。另外财报显示，鉴于产品组合考虑，公司决定终止每周一次口服司美格鲁肽制剂的Ⅰ期临床研究。->点击文末阅读原文，解锁完整双语新闻

In the first quarter, sales of the top three products Amgen gained from its $27.8 billion acquisition of Horizon Therapeutics fell far short of analyst expectations, with each seeing a double-digit sequential sales decline. It’s been 19 months since Amgen completed its $27.8 billion acquisition of Horizon Therapeutics, and the California company is still struggling to build momentum for three of the prized possessions of the deal—rare disease drugs Uplizna, Krystexxa and Tepezza.When Amgen presented its first-quarter earnings Thursday, none of the trio met analyst expectations. With sales of $91 million, Uplizna came up $20 million short of the consensus projection. Meanwhile, Krystexxa’s haul of $236 million was $57 million shy of expectations, and Tepezza’s $381 million figure was $69 million off the mark.The shortfall for the Horizon products came during a quarter in which most of the company’s other treatments exceeded expectations. In fact, Amgen’s overall revenue of $8.1 billion was a 9% increase year over year and topped the analyst consensus. The lack of success for the Horizon drugs is apparently becoming a sore subject for Amgen execs. During a conference call, after an analyst asked about the stagnant sales of Tepezza and referred to a “couple years” since the Horizon buyout, Chief Financial Officer Peter Griffith was quick to make a correction.“Just a reminder that the transaction closed in October of 2023,” Griffith said. “It’s been about a year and a half, although so much has happened in the world it might feel like more than that.”The most vexing Horizon product has been with Tepezza, which remains the lone drug on the market for thyroid eye disease. In its second full year on the market under Horizon, in 2022, it generated $1.96 billion in revenue. But, in the following year, sales came in at $1.77 billion, followed by $1.85 billion last year, when there were signs that Tepezza was rallying.But the $381 million quarterly result for the treatment was a stunner—it’s lowest figure for a three-month period since the first quarter of 2021 and a 17% sequential decline.“Sales of Tepezza and Krystexxa were adversely impacted in the quarter by changes to U.S. wholesaler inventory levels," Amgen’s chief commercial officer Murdo Gordon explained. "We do not expect similar deductions in inventory levels for the remainder of the year."But the result sounded an alarm bell with Mizuho Securities analyst Salim Syed, who noted the 9% decline in volume and 8% decrease in inventory levels, which “likely put the Horizon acquisition into even more question,” he wrote in a note to investors.Gordon explained that the initial uptake of Tepezza was strong as it was a long-awaited answer for people who had serious cases of the eye disease and were readily prescribed the treatment from plastic surgeons. To grow sales, Tepezza needs to secure more prescriptions from general ophthalmologist and endocrinologists, he added.But tapping this segment of the market “may be more challenging to penetrate than previously communicated by the company,” analysts from Citi wrote in a note to clients.Amgen is far from abandoning hope for Tepezza. The company recently gained a thumbs-up from Europe’s Committee for Medicinal Products for Human Use nd is ready to launch there upon an expected approval. An additional edge Amgen could secure to help spur sales would be to earn approval for a subcutaneous version of Tepezza, as opposed to the 60- to 90-minute infusions patients undergo every three weeks as it stands. A subQ option would allow patients to receive the treatment faster and in many more settings than at infusion centers. Testing on the formulation began last year.On a much smaller scale, sales also were disappointing for Uplizna, which fell sequentially from $101 million in the fourth quarter to $91 million in the first.But help has already arrived in the form of a label expansion last month, making Uplizna the first drug to win an FDA approval for immunoglobulin G4-related disease (IgG4-RD), a disease that affects 20,000 patients in the U.S. and has no standard of care. Additionally, Amgen announced Thursday that it has secured an FDA decision date of Dec. 14 for Uplizna to treat patients with generalized myasthenia gravis (gMG).With respect to all of the Horizon products, Amgen’s message on Thursday was to give them more time.“It’s a very young portfolio of products where we’re really just beginning to address the severe diseases that these drugs treat,” Jay Bradner, Amgen’s R&D chief, said. “Whether it’s Tepezza, Uplizna, Krystexxa or Tavneos, these are going to be key growth-driving products for us over the long haul.”